Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
3.530
+0.330 (10.31%)
At close: Apr 25, 2025, 4:00 PM
3.510
-0.020 (-0.57%)
After-hours: Apr 25, 2025, 4:19 PM EDT
Company Description
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States.
The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product.
The company was founded in 2008 and is based in Mainz, Germany.
Mainz Biomed N.V.
| Country | Germany |
| Founded | 2021 |
| IPO Date | Nov 5, 2021 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Guido Baechler |
Contact Details
Address: Robert Koch Strasse 50 Mainz, 55129 Germany | |
| Phone | 49 6131 554 2860 |
| Website | mainzbiomed.com |
Stock Details
| Ticker Symbol | MYNZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001874252 |
| CUSIP Number | N5436L101 |
| ISIN Number | NL0015000LC2 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Guido Baechler | Chief Executive Officer and Executive Director |
| Dr. Christopher Von Toerne P.M.P., Ph.D. | Chief Operating Officer |
| Dr. Frank Krieg-Schneider | Chief Technology Officer |
| Dr. Moritz Eidens Ph.D. | Chief Science Officer and Executive Director |
| Stefan Erlach | Head of Human Resources |
| Philipp Freese | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2025 | 6-K | Report of foreign issuer |
| Mar 31, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 13, 2025 | 6-K | Report of foreign issuer |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Jan 27, 2025 | 6-K | Report of foreign issuer |
| Jan 14, 2025 | 6-K | Report of foreign issuer |
| Dec 16, 2024 | 6-K | Report of foreign issuer |
| Dec 16, 2024 | 424B3 | Prospectus |
| Dec 13, 2024 | 6-K | Report of foreign issuer |
| Dec 12, 2024 | EFFECT | Notice of Effectiveness |